Related Experiment Videos
Cicaprost inhibits metastases of animal tumors
1Research Laboratories of Schering AG Berlin, FRG.
Abstract:
Since an involvement of platelet aggregation in the metastatic process has been found, platelet activation inhibitors were investigated for their potential to reduce tumor metastases. Recent in-vitro and in-vivo investigations showed an antimetastatic effect of prostacyclin (PGI2) and stable prostacyclin analogues. This study concentrates on the effect of the stable prostacyclin analogue Cicaprost (Schering AG) on tumor metastases in two metastasizing tumors of rodents. C57BL/6 mice bearing s.c.-implanted M5076 reticulum sarcoma were treated with Cicaprost in doses of 0.1-1.0 mg/kg throughout the experiment. Cicaprost in all doses tested reduced the number of liver metastases in a statistically significant manner. The 1.0 mg/kg dose, which decreases the median number of liver metastases to more than 93% compared to the control, was most effective. Cicaprost in the 0.5 mg/kg dose reduced the number of liver metastases in mice bearing i.v.-implanted M5076 reticulum sarcoma. In Cop-Fisher rats bearing s.c.-implanted spontaneously metastasizing R3327 MAT Lu prostate carcinoma, Cicaprost in a dose of 1.0 mg/kg p.o. daily strongly reduced the number of lung metastases. These results indicate that Cicaprost is a potent inhibitor of tumor metastases in different tumor models in rodents.
Insights
The stable prostacyclin analogue Cicaprost effectively reduced tumor metastases in rodent models. This study highlights Cicaprost
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis Research
Background:
- Platelet aggregation plays a role in tumor metastasis.
- Prostacyclin (PGI2) and its analogues have demonstrated antimetastatic effects in prior research.
- Platelet activation inhibitors are being explored for their potential to reduce cancer spread.
Purpose of the Study:
- To investigate the antimetastatic efficacy of the stable prostacyclin analogue Cicaprost.
- To evaluate Cicaprost's effect on tumor metastases in two distinct rodent models.
- To determine dose-dependent effects of Cicaprost on metastasis reduction.
Main Methods:
- Administration of Cicaprost at varying doses (0.1-1.0 mg/kg) to C57BL/6 mice with subcutaneous M5076 reticulum sarcoma.
- Treatment of mice bearing intravenous M5076 reticulum sarcoma with Cicaprost (0.5 mg/kg).
- Oral administration of Cicaprost (1.0 mg/kg daily) to Cop-Fisher rats with subcutaneous R3327 MAT Lu prostate carcinoma.
Main Results:
- Cicaprost significantly reduced liver metastases in mice with M5076 reticulum sarcoma across all tested doses.
- A dose of 1.0 mg/kg Cicaprost led to a >93% decrease in median liver metastases.
- Cicaprost (1.0 mg/kg) markedly reduced lung metastases in rats with R3327 MAT Lu prostate carcinoma.
Conclusions:
- Cicaprost demonstrates potent antimetastatic activity in multiple rodent tumor models.
- The findings suggest Cicaprost's potential as a therapeutic agent to inhibit cancer metastasis.
- Further research into prostacyclin analogues for cancer treatment is warranted.